Risk factors
Alaunos Therapeutics (TCRT) risk factors
Item 1A of every Alaunos Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors42 risks18 new37 dropped11 reworded
Alaunos Therapeutics shifted away from broad strategic alternatives to focus entirely on its early preclinical Obesity and Metabolic Disorders Program.
Filed Mar 31, 2026 - FY2024 10-K risk factors61 risks
Company is evaluating strategic alternatives following a 95% workforce reduction in August 2023. Future depends on finding a strategic transaction or liquidating assets. Licensed TCR-T cell therapies and clinical programs are currently suspended or uncertain.
Filed Mar 31, 2025